This Fool wants to make the most of the benefits a Stocks and Shares ISA provides. He's keen on these two stocks.

Constellation Energy and Vistra have been among the best-performing stocks this year, reflecting optimism around the companies' potential to capitalize on the power needs of artificial-intelligence ...

IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

Our Fool likes the look of these stock market juggernauts for the chunky passive income they throw off, not to mention their ...

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

GET MORE AI-GENERATED SIGNALS: September 19, 2024, 20:16 pm ET, BY Jeff W.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

In the past 60 days, estimates for Krystal Biotech’s 2024 EPS have increased from $2.09 to $2.38. The consensus estimate for 2025 earnings has improved from $4.33 to $7.31. Year to date, shares of ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Fulcrum Therapeutics (FULC) stock falls 70% as lead asset, losmapimod licensed from GSK (GSK) fails in a Phase 3 trial against a rare muscle disorder. Read more here.

It was a busy week for the biotech sector, with a lot of important data readouts and regulatory updates. Among these, Terns ...

Also Read: GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech. Interim data suggest the vaccine candidates have an acceptable safety and ...

GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in ...